Wednesday, February 10, 2010, 7:18pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

GenVec Inc. (GNVC)

At 5:00AM SGT: 1.72 USD   0.00 (0.00%)  
 MORE ON GNVC 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 GenVec, Inc. (NGM:GNVC) Delayed quote dataEdit
Last Trade:1.72 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:1.72
Open:N/A
Bid:1.22 x 1000
Ask:1.98 x 1400
1y Target Est:4.00
Day's Range:N/A - N/A
52wk Range:0.33 - 3.34
Volume:0
Avg Vol (3m):3,662,130
Market Cap:182.90M
P/E (ttm):N/A
EPS (ttm):-0.22
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add GNVC to Portfolio   Download Data

 HEADLINES 
•3 Stocks in a Tailspin
at Motley Fool (Thu, Feb 4)
•10 Biotech Stocks on Clinical Trials Watch
at TheStreet.com (Thu, Feb 4)
•Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering
PR Newswire (Tue, Feb 2)
•GenVec to Present at the 12th Annual BIO CEO & Investor Conference
PR Newswire (Mon, Feb 1)
•Biotech Stock Mailbag: Keryx Biopharmaceuticals
at TheStreet.com (Fri, Jan 29)
•Wednesday's Biggest Stock Stars
at Motley Fool (Thu, Jan 28)
•More Biotech Volatility: Celsius Holdings, Genvec
at Seeking Alpha (Thu, Jan 28)
•GENVEC INC Files SEC form 8-K, Financial Statements and Exhibits
EDGAR Online (Thu, Jan 28)
•Jackson Hewitt Tax Service, GenVec: Biggest Price Decliners (JTX, GNVC)
at The Wall Street Journal Online (Thu, Jan 28)
•Conolog, Jackson Hewitt: Late Day Volume Plays
at TheStreet.com (Thu, Jan 28)
•Jackson Hewitt Tax Service, GenVec: Biggest Price Decliners (MLP, GNVC)
at The Wall Street Journal Online (Thu, Jan 28)
More Headlines for GNVC...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.17
EPS Est (in 2 years) (Dec-10) :-0.18
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inop...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices